Screening patients with hypertrophic cardiomyopathy for Fabry disease using a filter-paper test: The FOCUS study

Heart

Volumn 97, Issue 2, 2011, Pages 131-136

  Hagège, Albert A ^a   Caudron, Eric ^b,c   Damy, Thibaud ^d   Roudaut, Raymond ^e   Millaire, Alain ^f   Etchecopar Chevreuil, Caroline ^g   Tran, Thi Chien ^c   Jabbour, Firas ^c   Boucly, Catherine ^c   Prognon, Patrice ^b   Charron, Philippe ^h   Germain, Dominique P ^c,i  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b University Paris Saclay   (France)

^c RAYMOND POINCARÉ HOSPITAL   (France)

^d HENRI MONDOR HOSPITAL   (France)

^e HAUT LÉVÊQUE HOSPITAL   (France)

^f LILLE UNIVERSITY HOSPITAL   (France)

^g DUPUYTREN UNIVERSITY HOSPITAL   (France)

^h PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

ⁱ LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSIDASE;

ADULT; AGED; ARTICLE; ATRIOVENTRICULAR BLOCK; BLOOD ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; ENZYME ACTIVITY; FABRY DISEASE; FEMALE; FILTER PAPER TEST; GENOTYPE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; PACEMAKER; PRIORITY JOURNAL;

EID: 78651237588     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2010.200188     Document Type: Article

References (28)

1. Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2008;29:270-6.
2. Maron BJ, McKenna WJ, Danielson GK, et al. American College of Cardiology/ European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. Eur Heart J 2003;24:1965-91.
3. Linhart A, Kampmann C, Zamorano JL, et al. Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. Eur Heart J 2007;28:1228-35. (Pubitemid 47343855)
4. Weidemann F, Niemann M, Breunig F, et al. Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation 2009;119:524-9.
5. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 2001;38:750-60.
6. Kampmann C, Linhart A, Baehner F, et al. Onset and progression of the Anderson-Fabry disease related cardiomyopathy. Int J Cardiol 2008;130:367-73.
7. Sachdev B, Takenaka T, Teraguchi H, et al. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation 2002;105:1407-11.
8. Waldek S, Patel MR, Banikazemi M, et al. Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry. Genet Med 2009;11:790-6.
9. Germain DP, Waldek S, Banikazemi M, et al. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol 2007;18:1547-57.
10. Kovacevic-Preradovic T, Zuber M, Attenhofer Jost CH, et al. Anderson-Fabry disease: long-term echocardiographic follow-up under enzyme replacement therapy. Eur J Echocardiogr 2008;9:729-35.
11. Nakao S, Takenaka T, Maeda M, et al. An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med 1995;333:288-93.
12. Arad M, Maron BJ, Gorham JM, et al. Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N Engl J Med 2005;352:362-72.
13. Monserrat L, Gimeno-Blanes JR, Marin F, et al. Prevalence of Fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2007;50:2399-403.
14. Chimenti C, Pieroni M, Morgante E, et al. Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy. Circulation 2004;110:1047-53.
15. Andrade J, Waters PJ, Singh RS, et al. Screening for Fabry disease in patients with chronic kidney disease: limitations of plasma alpha-galactosidase assay as a screening test. Clin J Am Soc Nephrol 2008;3:139-45.
16. Maron MS, Maron BJ, Harrigan C, et al. Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance. J Am Coll Cardiol 2009;54:220-8.
17. Chamoles NA, Blanco M, Gaggioli D. Fabry disease: enzymatic diagnosis in dried blood spots on filter paper. Clin Chim Acta 2001;308:195-6.
18. Shapiro LM, Kleinebenne A, McKenna WJ. The distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy: comparison to athletes and hypertensives. Eur Heart J 1985;6:967-74.
19. Caudron E, Moliere D, Zhou JY, et al. [Recent advances of Fabry disease screening for at risk population]. Med Sci (Paris) 2005;21:48-50.
20. Mayes JS, Scheerer JB, Sifers RN, et al. Differential assay for lysosomal alpha-galactosidases in human tissues and its application to Fabry's disease. Clin Chim Acta 1981;112:247-51.
21. Lukacs Z, Keil A, Kohlschutter A, et al. The ratio of alpha-galactosidase to beta-glucuronidase activities in dried blood for the identification of female Fabry disease patients. J Inherit Metab Dis 2005;28:803-5.
22. Lukacs Z, Hartung R, Beck M, et al. Direct comparison of enzyme measurements from dried blood and leukocytes from male and female Fabry disease patients. J Inherit Metab Dis 2007;30:614.
23. Germain DP. A new phenotype of Fabry disease with intermediate severity between the classical form and the cardiac variant. Contrib Nephrol 2001:234-40.
24. Linthorst GE, Bouwman MG, Wijburg FA, et al. Screening for Fabry disease in high risk populations: a systematic review. J Med Genet 2010;47:217-22.
25. Havndrup O, Christiansen M, Stoevring B, et al. Fabry disease mimicking hypertrophic cardiomyopathy: genetic screening needed for establishing the diagnosis in women. Eur J Heart Fail 2010;12:535-40.
26. Ommen SR, Nishimura RA, Edwards WD. Fabry disease: a mimic for obstructive hypertrophic cardiomyopathy? Heart 2003;89:929-30.
27. Magage S, Linhart A, Bultas J, et al. Fabry disease: percutaneous transluminal septal myocardial ablation markedly improved symptomatic left ventricular hypertrophy and outflow tract obstruction in a classically affected male. Echocardiography 2005;22:333-9.
28. Mehta A, Beck M, Elliott P, et al. Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data. Lancet 2009;374: 1986-96.